CANF vs CATX

Can-Fite Biopharma Ltd vs Perspective Therapeutics, Inc. — Valuation Comparison 2026

CANF

Pharmaceutical Preparations
Can-Fite Biopharma Ltd
Quality
2.2
out of 10
Value Trap
6
SAFE
Price
$3.35
Last close
Models
9/13
Active
VS

CATX

Pharmaceutical Preparations
Perspective Therapeutics, Inc.
Quality
4.6
out of 10
Value Trap
18
SAFE
Price
$3.94
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType CANF Fair ValueCANF Upside CATX Fair ValueCATX Upside
Bayesian DCF Intrinsic $0.87 -73.9% $1.23 -68.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.14 -36.2% $2.06 -47.8%
PWERM Option-Based $2.83 -15.6% $3.96 +0.5%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CANF vs CATX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CANF vs CATX — Which Stock Is More Undervalued?

CATX scores higher with a 4.6/10 quality rating vs CANF's 2.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Can-Fite Biopharma Ltd (CANF) and Perspective Therapeutics, Inc. (CATX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CANF currently trades at $3.35 with a QOC of 2.2/10, while CATX trades at $3.94 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).